RA Capital Buys $46.6M of Bambusa Stock, Anchoring $16 IPO
BBTX sits 18% above its 52-week low of $13.6 on light trading volume (0.3× avg).
Summary
RA Capital bought 2.95 million Bambusa shares for $46.6 million, including 2.5 million at the $16.00 IPO price, and converted 4.48 million preferred shares into common stock.
Key Events · Ownership and Investor Activity · BBTX
-
RA Capital Buys $46.6M in IPO
RA Capital entities purchased 2,953,820 shares for $46,639,957, including 2,335,109 shares at the $16.00 IPO price on 2026-11-02.
-
Pre-IPO Purchases at $14.23-$14.92
On 2026-10-30 the fund bought 189,909 shares at a weighted-average $14.23 (range $13.61-$14.58) and 263,911 shares at $14.92 (range $14.65-$15.00).
-
Preferred Converts One-for-One
4,475,938 Series A-1 and A-2 preferred shares automatically converted into common stock on 2026-11-02 prior to the IPO closing.
-
Stake Now 5.93M Shares
Post-transaction indirect holdings total 5,933,787 shares held via RA Capital Healthcare Fund and Nexus Fund III.
Analysis · BBTX · Life Sciences
A large anchor commitment from a sophisticated healthcare investor: RA Capital, a director and 10% owner, put real money into Bambusa's IPO, buying 2.95 million shares for $46.6 million, including 2.5 million shares at the $16.00 offering price on closing day. Alongside that, 4.48 million preferred shares converted one-for-one, clearing the pre-IPO capital structure. Purchases were made at $14.23-$16.00, so the fund was buying into the deal rather than selling. The main caveat is that this is a financial sponsor with board representation, not an operating executive, and its stake is now 5.93 million shares.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBTX was trading at $15.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $796.2M. The 52-week trading range was $13.60 to $17.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.